Pharmacokinetic Study of Topically Applied Veregen 15% Compared With Oral Intake of Green Tea Beverage
NCT ID: NCT01082302
Last Updated: 2010-09-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
43 participants
INTERVENTIONAL
2010-01-31
2010-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
oral intake of green tea beverage
Healthy volunteers are asked to drink a defined amount of green tea beverage over 7 days
Green Tea Beverage with defined catechin content
3 times daily oral intake over 7 days
Polyphenon E 15% ointment
3 times daily application of Polyphenon E 15% ointment on genital and perianal warts over 7 days
Polyphenon E (Veregen) 15% ointment
3 times daily application on genital and perianal warts over 7 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Polyphenon E (Veregen) 15% ointment
3 times daily application on genital and perianal warts over 7 days
Green Tea Beverage with defined catechin content
3 times daily oral intake over 7 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Male and female subjects, 18 years of age or older at the time of enrollment. Subjects will be stratified by gender.
2. Written informed consent.
3. Ability to comply with the requirements of the study.
For patients (treatment arm 1, additionally):
4. Clinical diagnosis of external genital and perianal warts which can be located: in men: over the glans penis, foreskin, penis shaft, and scrotum; in women: on the vulva; in both gender: in the inguinal, perineal, and perianal areas.
5. A total wart area of at least 100 mm² and a maximum of 2500 mm².
6. For women of child-bearing potential: negative pregnancy test and willingness to use two effective methods of contraception throughout their study participation is mandatory (oral contraceptives, hormone containing intrauterine device, depot injection, hormone implant, or sterilization (for contraception) plus condom (for prevention of reinfection). For male patients and partners of male patients who are of childbearing potential: use of two methods of effective contraception during the treatment period is mandatory (oral contraceptives, hormone containing intrauterine device, depot injection, hormone implant, or sterilization (for contraception) plus condom (for prevention of reinfection).
Exclusion Criteria
1. Participation in an investigational trial within 30 days prior to enrollment and for the whole study duration.
2. Any current uncontrolled infection.
3. Current known acute or chronic infection with Hepatitis virus B or C.
4. Known Human immunodeficiency virus infection.
5. Subjects with known history of chronic (diabetes, hypertension, gastritis, etc.) or consuming diseases (cancer, multiple sclerosis, etc.), chronic inflammation, or liver or renal insufficiency.
6. Any chronic or acute condition including the skin, susceptible, in the opinion of the investigator, of interfering with the evaluation of the drug effect.
7. Laboratory data above the upper normal range.
8. Systemic intake of virostatics within 30 days prior to enrollment and for the whole study duration, with the exception of acyclovir and the related drugs famciclovir and valaciclovir.
9. Systemic intake of immunosuppressive or immuno-modulatory medication or vaccination within 30 days prior to enrollment and for the whole study duration.
10. Organ allograft recipient.
11. Medication intake, including over the counter products and dietary supplements such as iodine, fluoride, or vitamins, which would interfere with study results, except paracetamol and oral contraceptives, within one week before and during the study course. Subjects are not allowed to consume green, black or Oolong tea as well as red wine or any other beverages or foods containing green tea extract within three days before each blood sampling visit.
12. For female patients: pregnancy or lactation.
13. Blood transfusion within 30 days prior to enrollment.
14. Subjects who are placed in an institution due to a judicial or official directive.
For patients (treatment arm 1, additionally):
15. Previous participation in a trial investigating sinecatechins in the treatment of external genital and perianal warts.
16. Treatment of external genital warts within 30 days prior to enrollment and for the whole study duration.
17. Current infection with Herpes genitalis or history of Herpes genitalis infection within the last 3 months prior to enrollment.
18. Any current and/or recurrent pathologically relevant genital infections other than genital warts.
19. Known allergies against any of the ingredients of the ointment.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Charité Research Organisation GmbH
OTHER
MediGene
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
MediGene
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Frank Wagner, Md, PD
Role: PRINCIPAL_INVESTIGATOR
Charité Research Organisation, Berlin
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Charité Research Organisation
Berlin, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2007-005432-88
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
CT 1022
Identifier Type: -
Identifier Source: org_study_id